Does thrombopoiesis in multiple myeloma patients depend on the stage of the disease?

Kamińska, Joanna; Koper, Olga M.; Mantur, M; Matowicka-Karna, Joanna; Sawicka-Powierza, Jolanta; Sokołowski, Jarosław; Kostur, Agnieszka; Kulczyńska, Agnieszka; Kłoczko, Janusz; Kemona, H

doi:10.1016/j.advms.2013.12.006

Cited by 8 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severity of thrombocytopenia has been correlated with the severity of multiple myeloma disease [24]. It also is associated commonly with bone marrow involvement and overall health status [25].…”

Section: Discussionmentioning

confidence: 99%

Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit

Lee

Shin

et al. 2017

PM&R

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit

Lee

Shin

et al. 2017

PM&R

View full text Add to dashboard Cite

show abstract

“…28 In our previous study, we observed that platelet count was lower in patients with MM than in controls and significantly decreased with the stage of the disease (however, thrombocytopenia was observed only in patients with stage III of MM). 29 Well-established biomarkers of platelet activation in vivo are platelet products such as thromboxane B2, P-selectin, and β-thromboglobulin. To this purpose, we analyzed β-thromboglobulin in patients with MM at different stages, compared with control subjects.…”

mentioning

confidence: 99%

Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines

Kamińska¹,

Koper²,

Dymicka-Piekarska³

et al. 2016

Polish Archives of Internal Medicine

Self Cite

View full text Add to dashboard Cite

“…It indirectly reflects the degree of bone marrow involvement, and may also result from hypersecretion of proinflammatory cytokines that inhibit the maturation of megakaryocytes and interfere with effective thrombopoesis [ 32 ]. Is is associated with shorter OS in patients with MM [ 33 ]. Jung et al showed that thrombocytopenia is also a risk factor of early mortality [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients

et al. 2018

View full text Add to dashboard Cite

Cereblon is a primary molecular target for immunomodulatory drugs. The aim of this study was to evaluate the influence of selected clinical and molecular factors including single nucleotide polymorphisms (SNPs) in CRBN gene on the efficacy of first line CTD (cyclophosphamide, thalidomide, dexamethasone) chemotherapy in patients with multiple myeloma. Study group consisted of 68 patients. Analysis of CRBN gene SNPs (rs6768972, rs1672753) was performed using Real-Time PCR genotyping technique. Median progression free survival (PFS) was 15 months and overall survival (OS) 79 months. Factors associated with significantly shorter OS included ISS 3, kidney disease, weight loss, anemia, thrombocytopenia, hypoalbuminemia, elevated β2-microglobuline and CRP. The presence of t(4;14) was associated with significantly shorter PFS and OS. Both examined SNPs proved to be statistically significant, independent predictive factors of efficacy of the CTD chemotherapy. The presence of AA genotype (rs6768972) correlated with longer median PFS (18 vs 9 months; HR=0.49,95% CI: 0.26-0.91, p=0.0062). Conversely, in the carriers of CC genotype (rs1672753) significantly shorter median PFS was observed (4 vs 16 months; HR=3.93, 95% CI: 0.26-59.64, p=0.0321). In conclusion, SNPs of the CRBN gene may be useful in qualifying patients for treatment with regimens containing thalidomide.

show abstract

Does thrombopoiesis in multiple myeloma patients depend on the stage of the disease?

Cited by 8 publications

References 23 publications

Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit

Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit

Serum soluble CD40L concentration depending on the stage of multiple myeloma and its correlation with selected angiogenic cytokines

Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients

Contact Info

Product

Resources

About